Journal
ONCOIMMUNOLOGY
Volume 2, Issue 4, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/onci.23660
Keywords
basal breast cancer; CCL5; CCR5; Maraviroc; metastasis; Vicriviroc
Categories
Funding
- NCI NIH HHS [R01 CA070896, R01 CA075503, R01 CA132115, P30 CA056036, R01 CA107382, R01 CA086072] Funding Source: Medline
Ask authors/readers for more resources
Recently, we have shown that the CCL5/CCR5 axis is active in patients affected by an aggressive basal subtype of breast cancer. Using preclinical models, we have demonstrated that CCR5 promotes breast cancer invasiveness and metastatic potential, while CCR5 inhibition abrogates them. Thus, CCR5 antagonists may constitute an alternative therapeutic approach for patients affected by metastatic basal breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available